Mavacamten safety and efficacy in a heart transplant patient exhibiting obstructive hypertrophic cardiomyopathy phenotype

Authors

Zaid Abood, Advocate Health - MidwestFollow
Asad Ghafoor, Advocate Health - MidwestFollow
Muddasir Ashraf, Advocate Health - MidwestFollow
Matthew Peters, Advocate Health - MidwestFollow
Patrycja Galazka, Advocate Health - MidwestFollow
Amanda Misicka, Advocate Health - MidwestFollow
M Fuad Jan, Advocate Health - MidwestFollow
Arshad Jahangir, Advocate Health - MidwestFollow
A Jamil Tajik, Advocate Health - MidwestFollow

Recommended Citation

Abood Z, Ghafoor A, Ashraf M, et al. Mavacamten Safety and Efficacy in a Heart Transplant Patient Exhibiting Obstructive Hypertrophic Cardiomyopathy Phenotype. JACC Case Rep. 2024;29(16):102454. Published 2024 Aug 21. doi:10.1016/j.jaccas.2024.102454

Affiliations

Aurora Sinai/Aurora St. Luke's Medical Centers

Abstract

Hypertrophic cardiomyopathy is the most common inherited cardiac disease, exhibiting diverse phenotypes. Obstructive hypertrophic cardiomyopathy occurs in about two-thirds of cases and carries a worse prognosis. Mavacamten use in heart transplant recipients is limited. This paper reports a recipient who developed severe symptomatic obstructive hypertrophic cardiomyopathy phenotype/phenocopy and was initiated on mavacamten.

Type

Article

PubMed ID

39295799